These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 707294)

  • 1. Isoproterenol as a potential pulmonary vasodilator in primary pulmonary hypertension.
    Daoud FS; Reeves JT; Kelly DB
    Am J Cardiol; 1978 Nov; 42(5):817-22. PubMed ID: 707294
    [No Abstract]   [Full Text] [Related]  

  • 2. Primary pulmonary hypertension; favorable effect of isoproterenol.
    Shettigar UR; Hultgren HN; Specter M; Martin R; Davies DH
    N Engl J Med; 1976 Dec; 295(25):1414-5. PubMed ID: 980096
    [No Abstract]   [Full Text] [Related]  

  • 3. Reassessment of the effects of vasodilator drugs in primary pulmonary hypertension: guidelines for determining a pulmonary vasodilator response.
    Rich S; Martinez J; Lam W; Levy PS; Rosen KM
    Am Heart J; 1983 Jan; 105(1):119-27. PubMed ID: 6849224
    [No Abstract]   [Full Text] [Related]  

  • 4. Primary pulmonary hypertension in a child. Response to pharmacologic agents.
    Satyanarayana Rao BN; Moller JH; Edwards JE
    Circulation; 1969 Oct; 40(4):583-7. PubMed ID: 5823553
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension.
    Ziegler JW; Ivy DD; Wiggins JW; Kinsella JP; Clarke WR; Abman SH
    Am J Respir Crit Care Med; 1998 Nov; 158(5 Pt 1):1388-95. PubMed ID: 9817684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unpredictable response to vasodilator therapy in primary pulmonary hypertension.
    Schmiedt MI; Shettigar UR; Siddique M; Barbier G; Bialow M; Carranza S
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):435-40. PubMed ID: 9726697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A problem in pulmonary hypertension. 1. The clinical course. A clinicopathologic conference from the Division of Pulmonary Diseases, Hahnemann Medical College and Hospital, Philadelphia.
    Chest; 1974 Jan; 65(1):69-75 contd. PubMed ID: 4809335
    [No Abstract]   [Full Text] [Related]  

  • 8. Isoproterenol in massive pulmonary embolism: haemodynamic and clinical effects.
    McDonald IG; Hirsh J; Hale GS; Cade JF; McCarthy RA
    Med J Aust; 1968 Aug; 2(5):201-5. PubMed ID: 5676200
    [No Abstract]   [Full Text] [Related]  

  • 9. Pulmonary vascular resistance in neonatal swine: response to right pulmonary artery occlusion, isoproterenol, and prostaglandin E1.
    Crombleholme TM; Adzick NS; Longaker MT; Bradley SM; Duncan BW; Jennings R; Verrier ED; Harrison MR
    J Pediatr Surg; 1990 Aug; 25(8):861-6. PubMed ID: 2401941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs.
    Evgenov OV; Ichinose F; Evgenov NV; Gnoth MJ; Falkowski GE; Chang Y; Bloch KD; Zapol WM
    Circulation; 2004 Oct; 110(15):2253-9. PubMed ID: 15466650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular effects of vasodilator therapy for pulmonary arterial hypertension.
    Rubin LJ
    Clin Chest Med; 1983 May; 4(2):309-19. PubMed ID: 6342925
    [No Abstract]   [Full Text] [Related]  

  • 12. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation.
    Opitz CF; Wensel R; Bettmann M; Schaffarczyk R; Linscheid M; Hetzer R; Ewert R
    Eur Heart J; 2003 Feb; 24(4):356-65. PubMed ID: 12581683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of vasodilators on pulmonary vascular resistance in patients with pulmonary hypertension.
    Zaloga GP; Chernow B; Holt MR; Hughes P; Pilley MP; Rainey TG; Lake CR
    Clin Pharm; 1983; 2(3):265-8. PubMed ID: 6192967
    [No Abstract]   [Full Text] [Related]  

  • 14. [Short- and long-term effects of the new oral prostacyclin analogue, beraprost sodium, in patients with severe pulmonary hypertension].
    Saji T; Ozawa Y; Nakayama T; Matsuura H; Hashiguchi R; Matsuo N; Muto H; Yamazaki J; Morishita T; Saito T
    J Cardiol; 1996 Apr; 27(4):197-205. PubMed ID: 8642506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse effect of hydralazine in patients with primary pulmonary hypertension.
    Kronzon I; Cohen M; Winer HE
    JAMA; 1982 Jun; 247(22):3112-4. PubMed ID: 7077805
    [No Abstract]   [Full Text] [Related]  

  • 16. Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension.
    Hermiller JB; Bambach D; Thompson MJ; Huss P; Fontana ME; Magorien RD; Unverferth DV; Leier CV
    Ann Intern Med; 1982 Oct; 97(4):480-9. PubMed ID: 7125407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise.
    Blumberg FC; Riegger GA; Pfeifer M
    Chest; 2002 May; 121(5):1566-71. PubMed ID: 12006445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aerosolized soluble nitric oxide donor improves oxygenation and pulmonary hypertension in acute lung injury.
    Jacobs BR; Brilli RJ; Ballard ET; Passerini DJ; Smith DJ
    Am J Respir Crit Care Med; 1998 Nov; 158(5 Pt 1):1536-42. PubMed ID: 9817705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside.
    Kieler-Jensen N; Lundin S; Ricksten SE
    J Heart Lung Transplant; 1995; 14(3):436-43. PubMed ID: 7654728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled nitric oxide versus intravenous vasodilators in severe pulmonary hypertension after cardiac surgery.
    Schmid ER; Bürki C; Engel MH; Schmidlin D; Tornic M; Seifert B
    Anesth Analg; 1999 Nov; 89(5):1108-15. PubMed ID: 10553820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.